A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines

2016 ◽  
Vol 36 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Kristen M. Cunanan ◽  
Joseph S. Koopmeiners
Keyword(s):  
Phase I ◽  
Cancer Vaccines ◽  
Trial Design ◽  
Therapeutic Cancer Vaccines

scholarly journals Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2908
Author(s):  
Constantin N. Baxevanis ◽  
Sotirios P. Fortis ◽  
Alexandros Ardavanis ◽  
Sonia A. Perez
Keyword(s):  
Clinical Trial ◽  
Cancer Immunotherapy ◽  
Phase Ii ◽  
Cancer Vaccines ◽  
Trial Design ◽  
Vaccine Trial ◽  
Phase Iii ◽  
Special Focus ◽  
Therapeutic Cancer Vaccines ◽  
The Impact

Therapeutic cancer vaccines have been at the forefront of cancer immunotherapy for more than 20 years, with promising results in phase I and—in some cases—phase II clinical trials, but with failures in large phase III studies. After dozens of clinical studies, only Dendreon’s dendritic cell vaccine Sipuleucel-T has succeeded in receiving US FDA approval for the treatment of metastatic castrate-resistant prostate cancer. Although scientists working on cancer immunotherapy feel that this is an essential breakthrough for the field, they still expect that new vaccine regimens will yield better clinical benefits compared to the four months prolonged median overall survival (OS) Sipuleucel-T demonstrated in the IMPACT phase III clinical trial. Clinical development of cancer vaccines has been unsuccessful due to failures either in randomized phase II or—even worse—phase III trials. Thus, rigorous re-evaluation of these trials is urgently required in order to redefine aspects and optimize the benefits offered by therapeutic cancer vaccines. The scope of this review is to provide to the reader our thoughts on the key challenges in maximizing the therapeutic potentials of cancer vaccines, with a special focus on issues that touch upon clinical trial design.

Combining radiation and therapeutic cancer vaccines: a synergistic approach

2012 ◽  
Vol 1 (4) ◽  
pp. 325-335
Author(s):  
Christopher R Heery ◽  
James W Hodge ◽  
James L Gulley
Keyword(s):  
Cancer Vaccines ◽  
Synergistic Approach ◽  
Therapeutic Cancer Vaccines

scholarly journals Dendritic-Cell-Based Therapeutic Cancer Vaccines

Immunity ◽  
2013 ◽  
Vol 39 (1) ◽  
pp. 38-48 ◽  
Author(s):  
Karolina Palucka ◽  
Jacques Banchereau
Keyword(s):  
Dendritic Cell ◽  
Cancer Vaccines ◽  
Therapeutic Cancer Vaccines
Sign in / Sign up

Export Citation Format

Share Document